The stock's rise snapped a five-day losing streak.
Zacks.com on MSN6h
Regeneron Gains 13.5% Year to date: How to Play the Stock?Shares of Regeneron Pharmaceuticals, Inc. REGN have gained 13.5% in the year so far against the industry’s decline of 2.8%.
Zacks.com on MSN8h
NTLA Begins Phase III Study on Hereditary Angioedema CandidateIntellia Therapeutics, Inc. NTLA announced that it has initiated the pivotal phase III HAELO study evaluating NTLA-2002 for ...
Ana Baramidze, MD, PhD, discussed 5-year follow-up results from the EMPOWER-Lung study evaluating cemiplimab vs chemotherapy ...
For the biopharma industry to match the pace of genomic innovations and speed new therapies to market, it will need to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback